author_facet Gadzinski, Adam J.
Greene, Kirsten L
Carroll, Peter
Ryan, Charles J.
Feng, Felix Y
Hope, Tom
Gadzinski, Adam J.
Greene, Kirsten L
Carroll, Peter
Ryan, Charles J.
Feng, Felix Y
Hope, Tom
author Gadzinski, Adam J.
Greene, Kirsten L
Carroll, Peter
Ryan, Charles J.
Feng, Felix Y
Hope, Tom
spellingShingle Gadzinski, Adam J.
Greene, Kirsten L
Carroll, Peter
Ryan, Charles J.
Feng, Felix Y
Hope, Tom
Journal of Clinical Oncology
Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
Cancer Research
Oncology
author_sort gadzinski, adam j.
spelling Gadzinski, Adam J. Greene, Kirsten L Carroll, Peter Ryan, Charles J. Feng, Felix Y Hope, Tom 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2018.36.6_suppl.236 <jats:p> 236 </jats:p><jats:p> Background: Conventional imaging techniques infrequently detect the site of prostate cancer disease in men with biochemical recurrence following radical prostatectomy (RP). We examine the use of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) to determine the site of disease recurrence in these men. Methods: We retrospectively reviewed men with persistently detectable prostate specific antigen (PSA) and those with formal biochemical recurrence (PSA ≥ 0.2 ng/mL) following RP who underwent PSMA PET scan under our institution's prospective trials (NCT02918357 &amp; NCT02611882). We assessed the location of detected recurrences, and examined the distribution of recurrence location (prostate bed, pelvic lymph nodes (LN), and extra-pelvic disease) according to PSA at time of PET scan. Results: One hundred and fifty-eight men underwent PSMA PET after RP, 46% of men had previously undergone either adjuvant or salvage radiation therapy. Eleven men (7%) had the scan for persistently detectable PSA &lt; 0.2 and 93% of men had biochemical recurrence. At time of RP, 66% of men had ≥pT3a disease, 40% had positive surgical margins, and 18% had positive lymph nodes. Gleason grade at RP was ≤3+3 in 5% of men, 3+4 in 27%, 4+3 in 32% and ≥4+4 in 36%. Overall, 77% of men had a lesion detectable on PSMA PET. Men with higher PSA at time of scan had a higher prevalence of lesions, with all men PSA &gt; 6.0 having at least one lesion on PSMA PET (Table). Overall, we found extra-pelvic lesions in 44% of all men, and 58% of men with PSA ≥ 1.0. These are areas not typically covered by salvage radiation fields. Conclusions: PSMA PET detects lesions in a high proportion of men with biochemical recurrence following RP, with many lesions outside of the pelvis. This may facilitate more precise targeting of treatment areas for these patients. Clinical trial information: NCT02918357. Clinical trial information: NCT02611882. [Table: see text] </jats:p> Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. Journal of Clinical Oncology
doi_str_mv 10.1200/jco.2018.36.6_suppl.236
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjIzNg
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjIzNg
institution DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
imprint American Society of Clinical Oncology (ASCO), 2018
imprint_str_mv American Society of Clinical Oncology (ASCO), 2018
issn 0732-183X
1527-7755
issn_str_mv 0732-183X
1527-7755
language English
mega_collection American Society of Clinical Oncology (ASCO) (CrossRef)
match_str gadzinski2018detectionofprostatecancerlesionsusinggallium68psma11petinmenwithbiochemicalrecurrencefollowingradicalprostatectomy
publishDateSort 2018
publisher American Society of Clinical Oncology (ASCO)
recordtype ai
record_format ai
series Journal of Clinical Oncology
source_id 49
title Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_unstemmed Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_full Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_fullStr Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_full_unstemmed Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_short Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_sort detection of prostate cancer lesions using gallium-68 psma-11 pet in men with biochemical recurrence following radical prostatectomy.
topic Cancer Research
Oncology
url http://dx.doi.org/10.1200/jco.2018.36.6_suppl.236
publishDate 2018
physical 236-236
description <jats:p> 236 </jats:p><jats:p> Background: Conventional imaging techniques infrequently detect the site of prostate cancer disease in men with biochemical recurrence following radical prostatectomy (RP). We examine the use of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) to determine the site of disease recurrence in these men. Methods: We retrospectively reviewed men with persistently detectable prostate specific antigen (PSA) and those with formal biochemical recurrence (PSA ≥ 0.2 ng/mL) following RP who underwent PSMA PET scan under our institution's prospective trials (NCT02918357 &amp; NCT02611882). We assessed the location of detected recurrences, and examined the distribution of recurrence location (prostate bed, pelvic lymph nodes (LN), and extra-pelvic disease) according to PSA at time of PET scan. Results: One hundred and fifty-eight men underwent PSMA PET after RP, 46% of men had previously undergone either adjuvant or salvage radiation therapy. Eleven men (7%) had the scan for persistently detectable PSA &lt; 0.2 and 93% of men had biochemical recurrence. At time of RP, 66% of men had ≥pT3a disease, 40% had positive surgical margins, and 18% had positive lymph nodes. Gleason grade at RP was ≤3+3 in 5% of men, 3+4 in 27%, 4+3 in 32% and ≥4+4 in 36%. Overall, 77% of men had a lesion detectable on PSMA PET. Men with higher PSA at time of scan had a higher prevalence of lesions, with all men PSA &gt; 6.0 having at least one lesion on PSMA PET (Table). Overall, we found extra-pelvic lesions in 44% of all men, and 58% of men with PSA ≥ 1.0. These are areas not typically covered by salvage radiation fields. Conclusions: PSMA PET detects lesions in a high proportion of men with biochemical recurrence following RP, with many lesions outside of the pelvis. This may facilitate more precise targeting of treatment areas for these patients. Clinical trial information: NCT02918357. Clinical trial information: NCT02611882. [Table: see text] </jats:p>
container_issue 6_suppl
container_start_page 236
container_title Journal of Clinical Oncology
container_volume 36
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792333515541446658
geogr_code not assigned
last_indexed 2024-03-01T14:13:59.981Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Detection+of+prostate+cancer+lesions+using+Gallium-68+PSMA-11+PET+in+men+with+biochemical+recurrence+following+radical+prostatectomy.&rft.date=2018-02-20&genre=article&issn=1527-7755&volume=36&issue=6_suppl&spage=236&epage=236&pages=236-236&jtitle=Journal+of+Clinical+Oncology&atitle=Detection+of+prostate+cancer+lesions+using+Gallium-68+PSMA-11+PET+in+men+with+biochemical+recurrence+following+radical+prostatectomy.&aulast=Hope&aufirst=Tom&rft_id=info%3Adoi%2F10.1200%2Fjco.2018.36.6_suppl.236&rft.language%5B0%5D=eng
SOLR
_version_ 1792333515541446658
author Gadzinski, Adam J., Greene, Kirsten L, Carroll, Peter, Ryan, Charles J., Feng, Felix Y, Hope, Tom
author_facet Gadzinski, Adam J., Greene, Kirsten L, Carroll, Peter, Ryan, Charles J., Feng, Felix Y, Hope, Tom, Gadzinski, Adam J., Greene, Kirsten L, Carroll, Peter, Ryan, Charles J., Feng, Felix Y, Hope, Tom
author_sort gadzinski, adam j.
container_issue 6_suppl
container_start_page 236
container_title Journal of Clinical Oncology
container_volume 36
description <jats:p> 236 </jats:p><jats:p> Background: Conventional imaging techniques infrequently detect the site of prostate cancer disease in men with biochemical recurrence following radical prostatectomy (RP). We examine the use of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) to determine the site of disease recurrence in these men. Methods: We retrospectively reviewed men with persistently detectable prostate specific antigen (PSA) and those with formal biochemical recurrence (PSA ≥ 0.2 ng/mL) following RP who underwent PSMA PET scan under our institution's prospective trials (NCT02918357 &amp; NCT02611882). We assessed the location of detected recurrences, and examined the distribution of recurrence location (prostate bed, pelvic lymph nodes (LN), and extra-pelvic disease) according to PSA at time of PET scan. Results: One hundred and fifty-eight men underwent PSMA PET after RP, 46% of men had previously undergone either adjuvant or salvage radiation therapy. Eleven men (7%) had the scan for persistently detectable PSA &lt; 0.2 and 93% of men had biochemical recurrence. At time of RP, 66% of men had ≥pT3a disease, 40% had positive surgical margins, and 18% had positive lymph nodes. Gleason grade at RP was ≤3+3 in 5% of men, 3+4 in 27%, 4+3 in 32% and ≥4+4 in 36%. Overall, 77% of men had a lesion detectable on PSMA PET. Men with higher PSA at time of scan had a higher prevalence of lesions, with all men PSA &gt; 6.0 having at least one lesion on PSMA PET (Table). Overall, we found extra-pelvic lesions in 44% of all men, and 58% of men with PSA ≥ 1.0. These are areas not typically covered by salvage radiation fields. Conclusions: PSMA PET detects lesions in a high proportion of men with biochemical recurrence following RP, with many lesions outside of the pelvis. This may facilitate more precise targeting of treatment areas for these patients. Clinical trial information: NCT02918357. Clinical trial information: NCT02611882. [Table: see text] </jats:p>
doi_str_mv 10.1200/jco.2018.36.6_suppl.236
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjIzNg
imprint American Society of Clinical Oncology (ASCO), 2018
imprint_str_mv American Society of Clinical Oncology (ASCO), 2018
institution DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1
issn 0732-183X, 1527-7755
issn_str_mv 0732-183X, 1527-7755
language English
last_indexed 2024-03-01T14:13:59.981Z
match_str gadzinski2018detectionofprostatecancerlesionsusinggallium68psma11petinmenwithbiochemicalrecurrencefollowingradicalprostatectomy
mega_collection American Society of Clinical Oncology (ASCO) (CrossRef)
physical 236-236
publishDate 2018
publishDateSort 2018
publisher American Society of Clinical Oncology (ASCO)
record_format ai
recordtype ai
series Journal of Clinical Oncology
source_id 49
spelling Gadzinski, Adam J. Greene, Kirsten L Carroll, Peter Ryan, Charles J. Feng, Felix Y Hope, Tom 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2018.36.6_suppl.236 <jats:p> 236 </jats:p><jats:p> Background: Conventional imaging techniques infrequently detect the site of prostate cancer disease in men with biochemical recurrence following radical prostatectomy (RP). We examine the use of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) to determine the site of disease recurrence in these men. Methods: We retrospectively reviewed men with persistently detectable prostate specific antigen (PSA) and those with formal biochemical recurrence (PSA ≥ 0.2 ng/mL) following RP who underwent PSMA PET scan under our institution's prospective trials (NCT02918357 &amp; NCT02611882). We assessed the location of detected recurrences, and examined the distribution of recurrence location (prostate bed, pelvic lymph nodes (LN), and extra-pelvic disease) according to PSA at time of PET scan. Results: One hundred and fifty-eight men underwent PSMA PET after RP, 46% of men had previously undergone either adjuvant or salvage radiation therapy. Eleven men (7%) had the scan for persistently detectable PSA &lt; 0.2 and 93% of men had biochemical recurrence. At time of RP, 66% of men had ≥pT3a disease, 40% had positive surgical margins, and 18% had positive lymph nodes. Gleason grade at RP was ≤3+3 in 5% of men, 3+4 in 27%, 4+3 in 32% and ≥4+4 in 36%. Overall, 77% of men had a lesion detectable on PSMA PET. Men with higher PSA at time of scan had a higher prevalence of lesions, with all men PSA &gt; 6.0 having at least one lesion on PSMA PET (Table). Overall, we found extra-pelvic lesions in 44% of all men, and 58% of men with PSA ≥ 1.0. These are areas not typically covered by salvage radiation fields. Conclusions: PSMA PET detects lesions in a high proportion of men with biochemical recurrence following RP, with many lesions outside of the pelvis. This may facilitate more precise targeting of treatment areas for these patients. Clinical trial information: NCT02918357. Clinical trial information: NCT02611882. [Table: see text] </jats:p> Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy. Journal of Clinical Oncology
spellingShingle Gadzinski, Adam J., Greene, Kirsten L, Carroll, Peter, Ryan, Charles J., Feng, Felix Y, Hope, Tom, Journal of Clinical Oncology, Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy., Cancer Research, Oncology
title Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_full Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_fullStr Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_full_unstemmed Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_short Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
title_sort detection of prostate cancer lesions using gallium-68 psma-11 pet in men with biochemical recurrence following radical prostatectomy.
title_unstemmed Detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy.
topic Cancer Research, Oncology
url http://dx.doi.org/10.1200/jco.2018.36.6_suppl.236